SLNO News and Press, Soleno Therapeutics Inc. From 01/09/24

Shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) traded at a new 52-week high today and are currently trading at $23.03. So far today, approximately 140.58k shares have been exchanged, as compared to an average 30-day volume of 383.77k shares. Soleno Therapeutics, Inc., a clinical-stage bio...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2024-01-02 16:24:57 ET More on Soleno Therapeutics Soleno Therapeutics: Impressive Data, But Never Forget Amarin Soleno draws Buy from Guggenheim on rare disease therapy Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data for S...

2023-12-26 15:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-21 18:59:00 ET A 10% lift to an analyst's stock price on Soleno Therapeutics (NASDAQ: SLNO) provided some nice lift to the biotech's shares on Thursday. They closed the day's trading session nearly 2.4% higher, more than double the percentage-rate increase of the S&P 5...

2023-12-14 14:28:07 ET More on Soleno Therapeutics Soleno Therapeutics: Impressive Data, But Never Forget Amarin Soleno draws Buy from Guggenheim on rare disease therapy Soleno Therapeutics prices its underwritten public offering at $20 per share Seeking Alph...

2023-11-26 10:47:19 ET Summary Soleno Therapeutics has seen a surge in stock value after positive data from Phase III trials of its Diazoxide Choline Extended-Release tablet for Prader-Willi Syndrome. The data showed improvements in body composition and hyperphagia-related behavio...

2023-11-21 13:57:21 ET More on Soleno Soleno Therapeutics prices its underwritten public offering at $20 per share Soleno Therapeutics proposes public offering of common stock Seeking Alpha’s Quant Rating on Soleno Therapeutics Historical earnings data...

Soleno Therapeutics Inc. (SLNO) is expected to report $-0.62 for Q3 2023

2023-11-07 08:18:14 ET More on Soleno Therapeutics Soleno Therapeutics prices its underwritten public offering at $20 per share Soleno Therapeutics proposes public offering of common stock Seeking Alpha’s Quant Rating on Soleno Therapeutics For further...